IRB-approved national study demonstrates the feasibility of routine pediatric blood collection performed by parents at home
O’Ryan Health today announced the release of results from a national, parent-administered pediatric blood collection study evaluating the RedDrop ONE capillary blood collection device, demonstrating that families can safely and reliably collect clinically meaningful blood samples from children at home. The study validates a new, family-centered model for pediatric blood collection that supports routine pediatricmonitoring and demonstrates the potential to reduce reliance on in-clinic phlebotomy.
Conducted as an independent, IRB-approved observational usability study, the researchevaluated parent-administered use of the RedDrop ONE capillary blood collection device in real-world home settings. Fifty children ages 3–17 participated across 19 U.S. states, including both healthy children and those with chronic or medically complex conditions. All enrollment, consent, instruction, sample collection, and return shipping were completed remotely, reflecting real-world adoption conditions rather than controlled clinical environments.
Parents successfully collected blood samples at home with high first-attempt success rates, low reported pain, short collection times, and strong overall acceptance. Collected blood and serum volumes consistently met or exceeded thresholds required for routine clinical testing, and laboratory analysis demonstrated strong analytical concordance between samples collected from the arm and leg during the same at-home collection session. Parents and children alike reported the experience as better than expected and preferable to traditional finger-prick or needle-based blood draws.
“This study shows that parents can play a central role in safely collecting clinically meaningful blood samples from their children at home,” said Tim Coleman, PhD, Architect of Operations and Co-Founder of O’Ryan Health. “By validating parent-administered pediatric blood collection in real-world conditions, we open the door to routine pediatric monitoring that fits into family life rather than disrupting it. This has important implications for medically fragile children, rural families, value-based care programs, and decentralized clinical research.”
Beyond device usability, the study demonstrated the feasibility of deploying pediatric blood collection nationally through O’Ryan Health’s Artemis Platform, an end-to-end logistics and informatics system designed to support virtual enrollment, guided collection, and compliant sample transport to a CLIA-certified laboratory for testing. Families completed at-home blood collection across 19 U.S. states, underscoring the scalability of home-based pediatric diagnostics without requiring new facilities or additional clinical workforce.
While lipid testing served as the representative clinical use case, the blood and serum volumes achieved support a wide range of downstream applications, including metabolic, proteomic, transcriptomic, and genomic analyses. These findings highlight the potential for home-based pediatric blood collection to support remote monitoring, longitudinal studies, and participation in research and care pathways that would otherwise require repeated clinic visits.
The study was funded by RedDrop Dx, Inc., the manufacturer of the RedDrop ONE device. All primary data collection was performed independently of O’Ryan Health, with parents collecting samples at home, and all laboratory testing was conducted by a CLIA-certified laboratory. O’Ryan Health served as an independent evaluator under contract, held IRB approval for the study, and was responsible for study coordination, data aggregation, analysis, interpretation, and reporting. RedDrop Dx had no role in study design, data collection, data analysis, data interpretation, or manuscript preparation.
The full manuscript is available as a preprint on the medRxiv prepublication server https://www.medrxiv.org/content/10.64898/2026.02.09.26345931v1
